Loading
A phase 1/2 trial of AST-3424 run by SWOG Cancer Research Network, active and no longer recruiting.
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL) is a phase 1/2 interventional study registered as NCT04315324 by SWOG Cancer Research Network, with 67 participants planned, started 2021-02-08. Conditions recorded: Recurrent T Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia, Refractory T Lymphoblastic Lymphoma and T Lymphoblastic Lymphoma. Interventions recorded: AKR1C3-activated Prodrug AST-3424, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Computed Tomography.
Shares OBI Pharma, Zhejiang Hisun Pharmaceutical, Ascentawits Pharmaceuticals, AST-3424 and the tag pipeline.
Shares Ascentawits Pharmaceuticals, AST-3424 and the tag pipeline.
Shares Ascentawits Pharmaceuticals and the tag pipeline.
Shares OBI Pharma and the tag pipeline.
Shares Ascentawits Pharmaceuticals and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/